Regeneron Pharmaceuticals (REGN) Non-Current Debt (2020 - 2026)

Regeneron Pharmaceuticals' Non-Current Debt history runs 7 years deep, the most recent figure standing at $2.0 billion for Q1 2026.

• In Q1 2026, Non-Current Debt changed 0.07% year-over-year to $2.0 billion; the TTM figure through Mar 2026 stood at $2.0 billion (changed 0.07% YoY), while the FY2025 annual figure was $2.0 billion, changed 0.08% from the prior year.
• Non-Current Debt was $2.0 billion for Q1 2026 at Regeneron Pharmaceuticals, roughly flat from $2.0 billion in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $2.0 billion in Q1 2026 to a low of $2.0 billion in Q1 2022.
• Historically, Non-Current Debt has averaged $2.0 billion across 5 years, with a median of $2.0 billion in 2024.
• The sharpest annual moves came in 2025 and 2026: Non-Current Debt grew 0.08% in 2025, then advanced 0.07% in 2026.
• A 5-year view of Non-Current Debt shows it stood at $2.0 billion in 2022, then rose by 0.08% to $2.0 billion in 2023, then grew by 0.08% to $2.0 billion in 2024, then climbed by 0.08% to $2.0 billion in 2025, then gained by 0.01% to $2.0 billion in 2026.
• The last three Non-Current Debt figures came in at $2.0 billion (Q1 2026), $2.0 billion (Q4 2025), and $2.0 billion (Q3 2025), per Business Quant data.